We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Stago Launches New My Qualiris QC Website for Brand-New User Experience

By LabMedica International staff writers
Posted on 28 Jan 2022
Image: My Qualiris QC (Photo courtesy of Stago)
Image: My Qualiris QC (Photo courtesy of Stago)

Stago (Paris, France) has launched its new My Qualiris QC website which provides a brand-new user experience with a 24/7 accessible web-application where the results of a user’s network are only a few clicks away.

My Qualiris QC provides an easy-to-use and comprehensive External Quality Assessment service that will meet the daily and special coagulation testing needs of laboratories. To optimize the quality approach of laboratories, Stago had introduced the My Qualiris QC program more than 10 years ago. Built on Stago's expertise in hemostasis, My Qualiris QC carries out complete comparisons designed in accordance to the NF EN ISO/IEC 17043 standard to ensure reliability of results.

My Qualiris QC estimates global performance through an extensive multi-level comparison to ensure system accuracy. Stago’s color-coded reports and alerts are easy to interpret, and they include haemostasis-specific indicators. The new My Qualiris QC website allows laboratories to manage different user profiles, submit results and consult the available reports whenever they want. The dedicated, secured, multilingual website also allows laboratories to archive their results for five years and download their participation certificate for audits.

Related Links:
Stago: My Qualiris QC

Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Benchtop Thermomixer
Biometra TS1 ThermoShaker
New
Electrolyte Analyzer
CBS-4000 (CBS-400)

Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
INTEGRA BIOSCIENCES AG